

TRENDS AND CAUSES OF CONGENITAL ANOMALIES IN THE PLEVEN REGION, BULGARIA

Kovacheva K^{1*}, Simeonova M¹, Velkova A²

***Corresponding author:** Katya Kovacheva, Department of Medical Genetics, Medical University, 1, Kliment Ohridski str., Pleven 5800, Bulgaria; Tel.: +359-6488-4169; Fax: +359-6482-2667; E-mail: katiakovach@gmail.com

ABSTRACT

We describe the secular trend, pattern and causes of congenital anomalies (CAs) in the Pleven region, Bulgaria. The source of the data was the regional population-based registry of CAs using criteria according to EUROCAT recommendations. During the period 1988-2006, 47,622 births were surveyed. A total of 1,225 cases of CAs were ascertained, giving a total prevalence of 25.72 [95% confidence interval (95% CI) 24.3 to 27.15 per 1,000 births. There was a significant increase in total prevalence from 17.76 per 1,000 births in 1988 to 29.40 in 2006 (χ^2 test for trend = 5.03; $p = 0.025$). Congenital heart disease (4.3 per 1,000 registered births), nervous system anomalies (3.3 per 1,000 births), limb defects (2.5 per 1,000 births) and neural tube defects (2.0 per 1,000 births) demonstrated the highest prevalence. There was a significant upward trend in the prevalence of some specific anomalies: digestive system, tumors, gastroschisis and non syndromal dysmorphic conditions. Genetic causes were identified in approximately 62% of all cases with CAs (chromosomal 8%, single gene defects 14%, multifactorial 40%).

The secular trend and particular pattern of CAs in the Pleven region require some potential underlying contributing factors to be considered: case ascertainment and diagnostic methods, and some environmental factors. These data draw attention to the need of further regional epidemiological studies. The high proportion of genetic causes emphasize the role of genetic services as an integral part of preventive medical care.

Keywords: Causes, Congenital anomalies, Prevalence, Regional registry, Secular trend

INTRODUCTION

Congenital anomalies (CAs) affect approximately 2-3% of all live births every year. Many of these defects are associated with serious health problems. Despite the geographical differences in the reported prevalence of CAs, they are still a leading cause of perinatal mortality and childhood morbidity [1-5]. Over the past 20 years, significant progress has been made in understanding the etiology of birth defects. There are many recognized causes of CAs, although in many cases no clear explanation can be established. The availability of antenatal and neonatal screening promotes the early diagnosis of CAs and provides information about their prevalence by using a regional registration approach. The good epidemiological data on the prevalence rate and pattern of birth defects in a specific region gives an opportunity of identifying some etiological factors and can be useful for their prevention.

¹ Department of Medical Genetics, Medical Faculty, Medical University, Pleven, Bulgaria

² Department of Social and Preventive Medicine, Faculty of Public Health, Medical University, Pleven, Bulgaria

The aim of this study was to describe the epidemiology of CAs in the region of Pleven (Bulgaria) over the period 1988-2006, and to answer the following questions: what is the prevalence of CAs? Has there been a secular change in the prevalence of CAs? What is the pattern of CAs? Which are the main causes of CAs and what is the role of genetic causes in their etiology?

METHODS

Study Population. The data in the study is based on the registry of CAs located at the University Hospital, City of Pleven, Bulgaria. This is a regional registry, not financially supported by the Ministry of Health, dealing with between 2,000 and 3,000 births per year. The registry is population based; University Hospital is the only hospital in the city and covers all deliveries of resident women within the boundaries of the Pleven region, a region with a decreasing number of inhabitants over the study period (from about 160,000 in 1988 to 140,500 in 2006). Invasive prenatal diagnosis is not available in the Pleven region. Over the period 1988-2006, a total of 47,622 births was surveyed, of which 47,229 (99.2%) were live births and 393 (0.8%) stillbirths.

Case Definition, Classification of Congenital Anomalies, and Ascertainment. The registry records all CAs identified in live births, stillbirths (official statistics of fetal deaths at ≥ 28 weeks gestation until 1992 and at ≥ 24 weeks gestation after 1992) including late miscarriages (fetal deaths of ≥ 20 weeks gestation), and terminations of pregnancy following prenatal diagnosis of CA. Early fetal deaths before the 20th week of gestation were excluded. The case definition and definition of CA were taken according to EUROCAT recommendations [6].

The congenital anomalies inclusion list comprised mainly major CAs and some minor anomalies without medical or cosmetic significance, either malformations or deformations (for example, isolated talipes). Some minor anomalies (EUROCAT list of minor anomalies for exclusion) were not recorded [6]. Cases with "isolated" anomalies were classified according to the EUROCAT classification by organ system or body region (*e.g.*, neural system, heart, digestive system). Cases with three or more CAs were classified as "multiple anomalies"

and comprised: chromosomal abnormalities, single gene and sporadic malformation syndromes [7], non syndromal dysmorphic conditions (sequence/association/complex), teratogenic syndromes (environmental abnormalities), multiple anomalies of unknown cause (malformation syndromes with unknown etiology and nosology). The anomalies assigned to the "multifactorial" category included the following isolated anomalies: neural tube defects (NTD); congenital heart disease (CHD); cleft palate and cleft lip; some cases of CAs of the nervous system (Dandy-Walker malformation, hydrocephaly due to congenital stenosis of the aqueduct of Sylvius); esophageal atresia/stenosis/tracheo-esophageal fistula; hypospadias; family cases of pes equinovarus and luxatio coxae congenita; congenital pyloric stenosis.

The criteria for inclusion of CHD cases were as follows: only cases of isolated cardiac defects in which the diagnosis was made by a cardiologist and confirmed by echocardiography or invasive criteria (catheter studies, surgery or pathological examination) were included. Functional or unspecified cardiac murmurs were excluded.

The ascertainment of the cases was mainly (90% of all cases) based on an active searching/screening for CAs conducted by neonatologists, gynecologists and clinical geneticists. Additional sources of information were hospital records (departments of obstetrics and gynecology, neonatology and pediatrics), records of pathological meetings, medical genetics records and stillbirths register. Whatever the source of ascertainment, at the end of every year all registered CA cases (particularly those with multiple anomalies) were carefully reviewed by a clinical geneticist to validate the diagnostic information, to check ID information and to record the final diagnosis. In all cases of CAs and death (in perinatal period or later), the data from pathological examinations were used for diagnostic validity. Maximum age at diagnosis was as follows: for most cases, up to the end of the first week after delivery; for selected malformations (CHD, urogenital), up to the end of the first year of life; in some cases (multiple anomalies) a follow-up was performed.

Along with the physical examination, additional methods were used for identification of the genetic causes of CAs: family history and pedigree; laboratory genetic testing (conventional cytoge-

netic analysis, biochemical and DNA analysis). In some cases (particularly those with multiple anomalies) dysmorphic evaluation and search for syndromes, features and references was done by a clinical geneticist, using different sources: dysmorphology literature, “Smith’s recognizable pattern of human malformation” [8], OMIM [7], London Dysmorphology Databases. Environmental causes were identified *via* interview (a careful history of pregnancy), questionnaire, clinical assessment and laboratory confirmation.

Data Analysis and Statistics. All analyses were based on the number of cases in the anomaly category of interest, not the number of anomalies. The study was approved by the Ethics Committee of the Medical University, Pleven, Buglaria. Informed consent was obtained from the parents in all cases of CAs.

The calculation of the total prevalence and live birth prevalence was conducted using the EURO-CAT recommendations [6]. Confidence intervals (95% CIs) were calculated for the total and live birth prevalence. The χ^2 test for trends was used to compare differences in prevalence over time. A *p* value of <0.05 was considered to be significant. Statistical analysis was performed using SPSS for Windows, v. 13.1.

RESULTS

During the study period (1988-2006), a total of 1,225 cases (1,115 live births, 72 stillbirths and 38 terminations of pregnancy) with CAs were ascertained. Table 1 presents the total number of CAs, the total, and live birth prevalence. The overall total prevalence of CAs was 25.72 (95% CI 24.3 to 27.15)

Table 1. Total and live birth prevalence of congenital anomalies in the Pleven region, Bulgaria, 1988-2006

Year	Number of CA Cases ^a	Number of Births ^b	Prevalence per 1,000 Births ^b (95% CI)	CA Cases in Live Births	Number of Live Births	Live Birth Prevalence per 1,000 (95% CI)
1988	64	3,604	17.76 (13.45 to 22.07)	59	3,586	16.45 (12.29 to 20.62)
1989	75	3,453	21.72 (16.86 to 26.58)	64	3,422	18.70 (14.16 to 23.24)
1990	64	3,421	18.71 (14.17 to 23.25)	61	3,409	17.89 (13.44 to 22.34)
1991	74	3,130	23.64 (18.32 to 28.96)	68	3,112	21.85 (16.71 to 26.99)
1992	80	2,905	27.54 (21.59 to 33.49)	75	2,875	26.09 (20.26 to 31.91)
1993	83	2,670	31.09 (24.50 to 37.67)	80	2,652	30.16 (23.66 to 36.68)
1994	69	2,627	26.26 (20.15 to 32.38)	64	2,607	24.54 (18.61 to 30.49)
1995	57	2,373	24.01 (17.86 to 30.18)	53	2,354	22.51 (16.52 to 28.51)
1996	60	2,370	25.32 (18.99 to 31.64)	56	2,351	23.82 (17.66 to 29.98)
1997	47	2,002	23.48 (16.84 to 30.11)	39	1,983	19.67 (13.56 to 25.78)
1998	60	2,099	28.58 (21.46 to 35.71)	55	2,083	26.40 (19.52 to 33.29)
1999	66	2,318	28.47 (21.70 to 35.24)	61	2,297	26.56 (19.98 to 33.13)
2000	48	2,229	21.53 (15.51 to 27.56)	47	2,209	21.28 (15.26 to 27.29)
2001	83	2,072	40.06 (31.61 to 48.50)	70	2,047	34.20 (26.32 to 42.07)
2002	64	1,940	33.00 (25.04 to 40.94)	58	1,914	30.30 (22.62 to 37.98)
2003	57	1,930	29.53 (21.98 to 37.09)	51	1,919	26.58 (19.38 to 33.77)
2004	49	2,124	23.07 (16.69 to 29.45)	47	2,111	22.26 (15.97 to 28.56)
2005	59	2,110	27.96 (20.93 to 35.00)	49	2,083	23.52 (17.02 to 30.03)
2006	66	2,245	29.40 (22.41 to 36.39)	58	2,215	26.18 (19.53 to 32.84)
Total	1,225	47,622	25.72 (24.3 to 27.15)	1,115	47,229	23.61 (22.24 to 24.98)

^a Congenital anomalies occurring in live births, stillbirths (including fetal deaths at ≥ 20 weeks of gestation) and terminated pregnancies.

^b Live births and stillbirths.

per 1,000 births over the study period. There was a significant increase in total prevalence from 17.76 (95% CI 13.45 to 22.07) per 1,000 births in 1988 to 29.40 (95% CI 22.41 to 36.39) in 2006 ($\chi^2 = 5.03$; $p = 0.025$). There were 47,229 live births and 1,115 live births with CAs, giving an overall live birth prevalence of 23.61 (95% CI 22.24 to 24.98) per 1,000 live births. There was a significant increase in live birth prevalence from 16.45 (95% CI 12.29 to 20.62) per 1,000 live births in 1988 to 26.18 (95% CI 19.53 to 32.84) in 2006 ($\chi^2 = 4.27$; $p = 0.039$).

Table 2 summarizes the main types of CA; number, proportion (% of all cases registered) and prevalence (per 1,000 registered births). Higher rates were notified for CHD (4.3 per 1,000), all nervous system CAs (3.3 per 1,000), limb defects (2.5 per 1,000). Neural tube defects showed a total prevalence of 2.0 per 1,000 per registered births, and about 20% of all cases of this defect resulted in termination of preg-

nancy. Most of the CHD cases (80%) were ascertained in the neonatal period of live born babies or in stillbirths (based on active screening). About 20% of the cases were diagnosed in the post neonatal period up to the end of the first year of life of the babies (some cases were identified *via* case records from the Department of Pediatrics, University Hospital, Pleven, Bulgaria).

The total prevalence of most CAs remained stable over the study period. However, there was a trend towards a significant increase in the total prevalence of specific anomalies: digestive system anomalies ($\chi^2 = 4.48$; $p = 0.034$), tumors (mostly teratomas) ($\chi^2 = 4.98$; $p = 0.026$), musculoskeletal and connective tissue anomalies (mainly gastroschisis) ($\chi^2 = 5.52$; $p = 0.019$), non syndromal dysmorphic conditions ($\chi^2 = 6.77$; $p = 0.009$).

Table 3 summarizes the main causes of registered CAs, number of cases, proportion (% of all

Table 2. The main types of congenital anomaly in all registered births (1988-2006), number, proportion (% of all cases) and prevalence (per 1,000 births)

Congenital Anomaly	Number of Cases	Proportion (%)	Total Prevalence per 1,000 Births
Isolated congenital anomalies^a			
Neural tube defects	96	7.8	2.02
Other CAs of nervous system	62	5.1	1.30
Eye	3	0.2	0.06
Ear	9	0.7	0.19
Congenital heart disease	204	16.7	4.29
Respiratory system	4	0.3	0.08
Cleft palate and cleft lip	51	4.2	1.07
Digestive system	66	5.4	1.39
External genital system	65	5.3	1.37
Internal urogenital system	22	1.8	0.46
Limb	121	9.9	2.54
Musculoskeletal and connective tissue	62	5.1	1.30
Skin	54	4.4	1.13
Endocrine glands	3	0.2	0.06
Tumors	10	0.8	0.21
Subtotal	832	68.0	17.47
Multiple congenital anomalies^b			
Chromosomal abnormalities	100	8.2	2.10
Single gene and sporadic malformation syndromes	109	8.9	2.29
Non syndromal conditions	40	3.3	0.84
Environmental abnormalities	34	2.8	0.71
Multiple anomalies of unknown etiology	110	9.0	2.31
Subtotal	393	32.0	8.25
Total	1,225	100.0	25.72

^a The classification of isolated CA is according to EUROCAT.

^b The classification of multiple CA is personal.

Table 3. Causes of congenital anomalies: number of case, proportion (% of all causes) and prevalence (per 1,000 registered births)

Cause	Number of Cases	Proportion (%)	Total Prevalence per 1,000 Births
Genetic			
Chromosomal	100	8.2	2.10
Single gene	168 ^a	13.7	3.53
Multifactorial	486	39.7	10.20
Subtotal	754	61.5	15.83
Environmental			
Drugs and chemicals	6	0.5	0.12
Infections	21	1.7	0.44
Maternal illness	9	0.7	0.19
Mechanical uterine factors	46	3.8	0.96
Subtotal	82	6.7	1.72
Unknown	389	31.8	8.17
Total	1225	100.0	25.72

^a The number of single gene disorders included single gene malformation syndromes plus isolated anomalies due to single gene defects.

cases registered) and prevalence (per 1,000 registered births). The most common CAs were those due to genetic causes (chromosomal, single gene, multifactorial), with a total prevalence of 15.8 per 1,000 registered births over the study period.

DISCUSSION

The congenital anomalies registered in this study comprise mostly major CAs and do not include some minor anomalies. It is therefore difficult to compare the determined total prevalence in our study with the data from other studies with a specific anomalies inclusion and exclusion list, as well as with a different way of calculation of the prevalence [6,9,10].

The overall total prevalence of CAs in this study was 25.72 per 1,000 births, which is similar to the total prevalence in other studies[11-14], and to the average rate for all full members' registries of EUROCAT (22.11 per 1000 births over time (1980-2005) [1]. The reported trend in prevalence of CAs is different for the registries. The registries in France, Belgium, Malta, Switzerland, Spain, Croatia and Italy reported increasing rates over time (1980-2005), while others like the British, Irish, Dutch and Danish registries, reported a declining trend.

The present study demonstrated an overall significant upward trend in the prevalence of CAs as a

whole (total and live birth prevalence) from 1988 to 2006 in the Pleven region. However, there was a significant increase in the total prevalence only of specific anomalies: digestive system, tumors, gastroschisis and non syndromal dysmorphic conditions. The potential underlying contributing factors that should be considered for explanation of regional and secular trends are: case ascertainment methods; improving antenatal screening; some demographic and environmental factors [9,15,16].

In this study, due to the relatively consistent methodology used in the registration of CA cases, we think that the case ascertainment and diagnostic methods play a minor role in data collection over time. In our study, the types of CA that have recently demonstrated an upward trend in prevalence have unclear genetics or a minor genetic impact and an important role of environmental factors in their etiology. That is why more attention should be paid to these factors in the future and further epidemiological studies are needed. For example, concerning gastroschisis there is a significant difference in the reported prevalence between EUROCAT registries, suggesting a geographical gradient in the prevalence of this defect [1,9]. The phenomenon of increasing gastroschisis prevalence in Europe (1980-2002), according to some authors [17], is not restricted to younger mothers only. In the present study, the upward trend in gastroschisis prevalence is without a

rise in the proportion of teenage mothers. There is evidence that maternal exposure to vasoconstrictive drugs and cigarette smoking may increase the risk of gastroschisis and small intestinal atresia [18]. This hypothesis is suitable to be tested in a future study, in relation to the changes in socioeconomic status of the Bulgarian population over the study period and expansion of some habits such as cigarette smoking.

The most common type of CAs we found were cardiac defects (16.7% of all anomalies), with a total prevalence rate of 4.3 per 1,000 births. The overall prevalence rate of CHD reported by EUROCAT over the period (1990-2005) was 6.77 per 1,000 births, with a variation of the rate seen across the different registries (from 4.49 per 1,000 for Zagreb, Croatia to 8.71 per 1,000 for Odense, Island of Fyn, Denmark) [1]. This variation reflects the difference of the availability and accuracy of antenatal diagnosis, the ascertainment of late post neonatally diagnosed cardiac defects, the possibility for close relation with a pediatric cardiologist and the expertise to accurately diagnose [9].

Neural tube defects are among the most common CAs that cause fetal and neonatal death around the world [5,19]. EUROCAT reported the overall prevalence rate of NTD at 1.05 per 1,000 births over the period 1990-2005 (Zagreb, Croatia 0.5 per 1,000 births, Glasgow, Scotland, UK 1.7 per 1,000, Paris, France 1.3 per 1,000) [1]. There is a variation (0% for Malta and Ireland, 22.0% for the Netherlands, 92.0% for France) in the proportion of NTD cases resulting in pregnancy termination, seen across the different registries and countries in Europe, influenced by the differences in screening policies, culture and legislation. The countries that did not have a policy for offering routine scans had a significantly lower prenatal detection rate of NTD [20].

The present study showed a relatively high prevalence rate of NTD in the Pleven region (2.0 per 1,000 births) compared to other registers and parts of Europe [1] and about 20.0% of all registered cases of NTD were detected in terminated pregnancies after prenatal diagnosis. Since in all the cases of prenatal diagnosis of NTD there was termination of the pregnancy, the data demonstrate inadequate prenatal screening for these defects in the Pleven region. Although in recent years the national policy

recommended periconceptional folic acid supplementation, the prevalence rate of NTD in the Pleven region remained stable over the study period. These factors raise the issue of introducing an official countrywide policy for routine ultrasound anomaly scanning as an element of prevention approaches.

Our study revealed three important findings: **1)** genetic components were identified in approximately 62.0% of all CA cases; 22.0% of all cases had a clear genetic cause (chromosomal 8.0% or single gene defects 14.0%) and 40.0% multifactorial etiology. The data demonstrate a high proportion of affected families with a high recurrence risk, and emphasize the importance of offering genetic counseling and prenatal diagnosis to mothers who have previously had an abnormal baby/pregnancy. **2)** The etiology of one-third of the CAs was unknown or unclear. **3)** Environmental causes were infrequent (approximately 7.0% of all CA cases).

In other studies [21-23], the reported genetic contribution of CAs is similar: chromosomal abnormalities 6.0-10.0%, single gene defects 7.0-17.0%, multifactorial etiology 20.0-30.0%. Environmental causes have been identified in 5.0-10.0% of birth defects and unknown causes in 40.0-50.0% of all cases. The lower proportion of CAs with unknown etiology established in our study may be due to the lower number of births (from 2,000 to 3,000 annually), which allows an accuracy of diagnosis and reflects the interest to identify a specific etiology.

In conclusion, the epidemiological data of this study suggest that 2.0-3.0% of all births (approximately 1 in 40 births every year) are associated with CAs. The particular pattern of CAs in the Pleven region and the increasing trend in prevalence of specific anomalies, draw attention to the role of specific environmental or may be local risk factors for those anomalies, and require further regional epidemiological studies. The high proportion of genetic factors in the causes of CA emphasize the importance of genetic counseling services as an integral part of preventive medical care.

ACKNOWLEDGMENTS

We wish to acknowledge colleagues at the Department of Obstetrics and Gynaecology, Clinic of Neonatology and all participants in the regional registry of congenital anomalies at the University

Hospital City of Pleven, for their assistance with data collection. We thank Professor Emil Simeonov (Department of Paediatrics, Medical Faculty, Sofia, Bulgaria) for his expert help in the analyses of the genetic causes.

REFERENCES

1. EUROCAT. Publications and data 1980-2005: Prevalence data tables (<http://www.eurocat.ulster.ac.uk/pubdata/tables.html>).
2. Kalter H. Five-decade international trends in the relation of perinatal mortality and congenital malformations: stillbirth and neonatal death compared. *Int J Epidemiol* 1991; 20(1): 173-179.
3. Rosano A, Botto LD, Botting B, Mastroiacovo P. Infant mortality and congenital anomalies from 1950 to 1994: an international perspective. *J Epidemiol Community Health* 2000; 54(9): 660-666.
4. Wen SW, Liu S, Joseph KS, Trouton K, Allen A. Regional patterns of infant mortality caused by lethal congenital anomalies. *Can J Public Health* 1999; 90(5): 316-319.
5. Wen SW, Liu S, Joseph KS, Rouleau J, Allen A. Patterns of infant mortality caused by major congenital anomalies. *Teratology* 2000; 61(5): 342-346.
6. EUROCAT. Guide 1.3 Instructions for the registration and surveillance of congenital anomalies. (<http://www.eurocat.ulster.ac.uk/surveillance/prevalencerates.html>).
7. McKusick V. Online Mendelian Inheritance in Man. Online website: <http://www.ncbi.nlm.nih.gov/omim>.
8. Jones KL. *Smith's Recognizable Patterns of Human Malformations*, 5th ed. Philadelphia: WB Saunders Company, 1997.
9. Rankin J, Pattenden S, Abramsky L, Boyd P, Jordan H, Stone D, Vrijheid D, Wellesly D, Dolk H. Prevalence of congenital anomalies in five British regions, 1991-99. *Arch Dis Child Fetal Neonatal Ed* 2005; 90(5): F374-379.
10. International Clearinghouse for Birth Defects Surveillance and Research. ICBDSR Annual Report 2006. Introduction. Calculation of rate (<http://www.icbdsr.org/filebank/documents/Report2006.pdf>).
11. EUROCAT. EUROCAT Annual Report to WHO 2005 (<http://www.eurocat.ulster.ac.uk/pdf/EUROCAT-Annual-Report-2005-for-WHO.pdf>).
12. Richards ID, Bentley HB, Glennly AM. A local congenital anomalies register: monitoring preventive interventions. *J Public Health Med* 1999; 21(1): 37-40.
13. Seto T, Nakagawa H, Morikawa Y, Nishijo M, Miura K, Kadoshima Y. Trend of congenital anomalies over 20 years ascertained by population-based monitoring in Ishikawa Prefecture, Japan. *Congenit Anom (Kyoto)* 2003; 43(4): 286-293.
14. Sipek A, Gregor V, Horacek J, Masatova D. Analysis of congenital defects contributing to perinatal mortality in Czech Republic. *Ceska Gynekol* 2003; 68(6): 389-394.
15. Dastgiri S, Stone DH, Le-Ha C, Gilmour WH. Prevalence and secular trend of congenital anomalies in Glasgow, UK. *Arch Dis Child* 2002; 86(4): 257-263.
16. Hobbs CA, Hopkins SE, Simmons CJ. Sources of variability in birth defects prevalence rates [abstract]. *Teratology* 2001; 64(suppl 1): S8-S13.
17. Loane M, Dolk H, Bradbury and a EUROCAT Working Group. Increasing prevalence of gastroschisis in Europe 1980-2002: a phenomenon restricted to younger mothers? *Paediatr Perinat Epidemiol* 2007; 21(4): 363-369.
18. Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposure with risks of gastroschisis and small intestinal atresia. *Epidemiology* 2003; 14(3): 349-354.
19. Dastgiri S, Gilmour WH, Stone DH. Survival of children born with congenital anomalies. *Arch Dis Child* 2003; 88(5): 391-394.
20. Boyd PA, de Vigan C, Khsohnood B, Loane M, Garne E, Dolk H, EUROCAT Working Group. Survey of prenatal screening policies in Europe for structure malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. *BJOG* 2008; 115(6): 689-696.
21. Jorde LB, Carey JC, Bamshad MJ, White RL. Clinical genetics and genetic counseling. In: Jorde LB, Carey JC, Bamshad MJ, White RL, Eds. *Medical Genetics*, 3rd ed. Missouri: Mosby, an affiliate of Elsevier 2003; 305-325.
22. Kalter H, Warkany J. Congenital malformation: etiological factors and their role in prevention. *N Engl J Med* 1983; 308(8): 424-431.
23. Turnpenny PD, Ellard S. Congenital abnormalities and dysmorphic syndromes. In: Turnpenny PD, Ellard S, Eds. *Emery's Elements of Medical Genetics*, 12th ed. London: Churchill Livingstone 2005; 247-262.